ライフサイエンスコーパス: mild cognitive impairment

1 ild Alzheimer's disease, 14 amyloid-positive mild cognitive impairment).

2 7%] were clinically normal and 537 [13%] had mild cognitive impairment).

3 articipants per arm in amyloid-beta-positive mild cognitive impairment).

4 rom a risk model developed for patients with mild cognitive impairment.

5 wareness and incident Alzheimer dementia and mild cognitive impairment.

6 nt of LLD participants met ADNI criteria for mild cognitive impairment.

7 phagocytosis by macrophages of patients with mild cognitive impairment.

8 an ND group that included participants with mild cognitive impairment.

9 ral cognitive function for older adults with mild cognitive impairment.

10 and psychosocial functioning in people with mild cognitive impairment.

11 ths, such as hippocampal subfield atrophy in mild cognitive impairment.

12 on spatially overlapped in the subjects with mild cognitive impairment.

13 grape juice are not exclusive to adults with mild cognitive impairment.

14 the preclinical stage, prior to the onset of mild cognitive impairment.

15 als with Alzheimer disease (AD) dementia and mild cognitive impairment.

16 depth in people with Alzheimer's Disease and Mild Cognitive Impairment.

17 impaired, and Ptau positive individuals with mild cognitive impairment.

18 ies, including hypertension, depression, and mild cognitive impairment.

19 paired (0.4 +/- 2.7%), amyloid-beta-negative mild cognitive impairment (-0.4 +/- 2.3%) or amyloid-bet

20 BP control significantly reduced the risk of mild cognitive impairment (14.6 vs 18.3 cases per 1000 p

21 Of the patients with early mild cognitive impairment, 147 had a 2-y follow-up scan,

22 imer's pathology (including amyloid-positive mild cognitive impairment), 19 patients with progressive

23 11 healthy controls, 223 patients with early mild cognitive impairment, 204 with late mild cognitive

24 Forty-five patients with mild cognitive impairment (26 with CSF Alzheimer's disea

25 signal was observed in amyloid-beta-positive mild cognitive impairment (3.0 +/- 5.3%) and Alzheimer's

26 A+T+(N)+ group had the largest proportion of mild cognitive impairment (30%).

27 mpaired individuals and 204 individuals with mild cognitive impairment (320 [53%] were female) were c

28 , 21% had normal cognitive function, 17% had mild cognitive impairment, 33% had moderate impairment,

29 and late-life hypotension had higher risk of mild cognitive impairment (37 affected individuals (odds

30 ulation norms, 37.2% of the participants had mild cognitive impairment, 43.7% had major cognitive imp

31 The overall effect on cognition in mild cognitive impairment across 17 trials was moderate

32 Mild cognitive impairment, AD dementia, and longitudinal

33 omparison with a matched archival dataset of mild cognitive impairment/Alzheimer's disease patients s

34 sonance imaging in 25 patients with amnestic mild cognitive impairment (aMCI) and 23 matched healthy

35 he default mode network (DMN) in 54 amnestic mild cognitive impairment (aMCI) and 46 AD.

36 In 38 older human adults with amnestic mild cognitive impairment (aMCI) or normative cognition,

37 n-pharmacological interventions for amnestic mild cognitive impairment (aMCI) patients.

38 s that exhibited change in previous amnestic Mild Cognitive Impairment (aMCI) trials.

39 e longitudinal study of people with amnestic mild cognitive impairment (aMCI) we assessed three param

40 jects, including 10 probable AD, 15 amnestic mild cognitive impairment (aMCI), and 10 cognitively hea

41 brain connectivity in patients with amnestic mild cognitive impairment (aMCI).

42 nd the impaired group by clinical phenotype (mild cognitive impairment, amnestic dementia, and non-am

43 tively normal (n = 42), clinically-diagnosed mild cognitive impairment (amyloid positive, n = 47, and

44 Alzheimer's disease (AD), non-AD dementia or mild cognitive impairment and 20 age-matched and sex-mat

45 ively normal subjects, 97 clinically defined mild cognitive impairment and 48 possible or probable Al

46 d with Alzheimer's disease (n = 50 with late mild cognitive impairment and 71 with Alzheimer's dement

47 dary cognitive outcomes included adjudicated mild cognitive impairment and a composite outcome of mil

48 cortical (18)F T807 binding in patients with mild cognitive impairment and AD dementia compared to cl

49 omal F-actin levels in postmortem brain from mild cognitive impairment and AD patients compared with

50 ver, our findings propose a new way to fight mild cognitive impairment and aging-related cognitive de

51 etected AHN in aged adults and patients with mild cognitive impairment and Alzheimer's disease (AD),

52 commentary on this article.Individuals with mild cognitive impairment and Alzheimer's disease clinic

53 itudinal changes in microglial activation in mild cognitive impairment and Alzheimer's disease subjec

54 l) and was significantly elevated for Abeta+ mild cognitive impairment and Alzheimer's disease subjec

55 gorization of neuroanatomical alterations in mild cognitive impairment and Alzheimer's disease that c

56 tsburgh compound B was high in subjects with mild cognitive impairment and Alzheimer's disease, while

57 ive aging and age-related conditions such as mild cognitive impairment and Alzheimer's disease.

58 o pure LATE-NC and one pure ADNC) donors had mild cognitive impairment and another two donors with LA

59 ients with AD in comparison to patients with mild cognitive impairment and control subjects.

60 erfusion has previously been associated with mild cognitive impairment and dementia in various cross-

61 ical data provide evidence that the risk for mild cognitive impairment and dementia is increased in i

62 fore the kindred's respective median ages at mild cognitive impairment and dementia onset.

63 viously been associated to CSF biomarkers in mild cognitive impairment and dementia patients.

64 s of daily living were pooled separately for mild cognitive impairment and dementia trials.

65 y no proven treatments to reduce the risk of mild cognitive impairment and dementia.

66 ncluding patients with Alzheimer disease and mild cognitive impairment and healthy volunteers.

67 myloid imaging specifically in subjects with mild cognitive impairment and in comparison with or in c

68 nclude ventricular CSF clearance deficits in mild cognitive impairment and multiple sclerosis.

69 miologic data supporting previous studies on mild cognitive impairment and progression to AD are revi

70 wn to improve memory function in adults with mild cognitive impairment and reduce blood pressure in h

71 A need exists for exploring mild cognitive impairment and risk of critical illness.

72 e of life and is detectable in patients with mild cognitive impairments and Alzheimer's disease.

73 's dementia and n = 14 with amyloid-positive mild cognitive impairment) and 29 healthy control subjec

74 o completed the study (5 healthy controls, 6 mild cognitive impairment, and 10 AD) received 370 MBq o

75 rly mild cognitive impairment, 204 with late mild cognitive impairment, and 132 with AD).

76 isease with no cognitive impairment, 86 with mild cognitive impairment, and 17 with dementia.

77 nitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with

78 er's disease (AD) patients, 40 subjects with mild cognitive impairment, and 40 controls with subjecti

79 nitively normal, 5 old cognitively normal, 5 mild cognitive impairment, and 5 Alzheimer disease (AD).

80 teral ventricular SUVR across the Alzheimer, mild cognitive impairment, and healthy control groups (P

81 ognitively normal controls, individuals with mild cognitive impairment, and individuals with AD to as

82 lthy control participants, participants with mild cognitive impairment, and participants with AD deme

83 d at baseline and follow-up in subjects with mild cognitive impairment, and this was compared with su

84 th a history of idiopathic falls, those with mild cognitive impairment, and those with Parkinson's di

85 number of DCX(+)PCNA(+) cells is reduced in mild cognitive impairments, and higher numbers of neurob

86 risk predictions of dementia in people with mild cognitive impairment are highly relevant for care p

87 fic commentary on this article.Subjects with mild cognitive impairment associated with cortical amylo

88 r's Coordinating Center on participants with mild cognitive impairment at baseline and either no neur

89 igation task can differentiate patients with mild cognitive impairment at low and high risk of develo

90 Secondary outcome was mild cognitive impairment at visit 6, based on the neuro

91 participants with a global CDR of 0.5 (i.e. mild cognitive impairment) at baseline, 126 with primary

92 ent represents a major challenge in PD, with mild cognitive impairment being a prodromal stage of PD

93 sure significantly reduced the occurrence of mild cognitive impairment, but not probable dementia.

94 ending Alzheimer dementia and its precursor, mild cognitive impairment, but prior studies have not sy

95 In the CNS, mild cognitive impairment can be attributed to obesity-i

96 Twenty-six (62%) of 42 mild cognitive impairment cases showed a raised cortical

97 Twenty-two (85%) of the 26 amyloid-positive mild cognitive impairment cases showed clusters of incre

98 flammation in a majority of amyloid positive mild cognitive impairment cases, its cortical distributi

99 nd would be present in most amyloid-positive mild cognitive impairment cases.

100 roinflammation (microglial activation) in 42 mild cognitive impairment cases.

101 e and follow-up microglial activation in the mild cognitive impairment cohort compared to controls we

102 reduction of 18% in microglial activation in mild cognitive impairment cohort over 14 months, which w

103 2, was down-regulated in persons with AD and mild cognitive impairment compared with controls.

104 renia, bipolar disorder, multiple sclerosis, mild cognitive impairment, dementia, and Parkinson's dis

105 re characterized as cognitively stable (CS), mild cognitive impairment-DS (MCI-DS), possible AD demen

106 d precursor protein (hAPP) and patients with mild cognitive impairment due to Alzheimer's disease (MC

107 yloid-positive patients meeting criteria for mild cognitive impairment due to Alzheimer's disease (n

108 for probable Alzheimer's disease dementia or mild cognitive impairment due to Alzheimer's disease, pr

109 ore biomarkers were strongly associated with mild cognitive impairment due to Alzheimer's disease.

110 (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer dis

111 (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer dis

112 f locus coeruleus dysfunction reminiscent of mild cognitive impairment/early Alzheimer's disease.

113 Slopes for individuals who developed mild cognitive impairment (eg, neuroticism: beta = 0.00;

114 Thirty subjects (eight mild cognitive impairment, eight Alzheimer's disease and

115 ic interaction among brain regions for early mild cognitive impairment (eMCI) diagnosis.

116 l diagnostic groups: cognitively unimpaired, mild cognitive impairment, frontotemporal dementia, prob

117 s glucose for energy, but in AD and amnestic mild cognitive impairment glucose metabolism is dramatic

118 were the most severe impaired domains in the mild cognitive impairment group, attention and visuospat

119 vanced clinical stage (Alzheimer's disease > mild cognitive impairment > older cognitively normal) an

120 re also associated with an increased risk of mild cognitive impairment (hazard ratio, 2.9; 95% CI, 1.

121 (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dys

122 was also associated with increased risk for mild cognitive impairment (HR, 1.47 [CI, 1.20 to 1.81];

123 decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicati

124 n of preexisting cerebrovascular disease and mild cognitive impairment in 1 each).

125 nimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study

126 Clinical factors associated with baseline mild cognitive impairment included age, male gender, str

127 Initiative (17 with AD dementia and 199 with mild cognitive impairment), including (18)F-florbetapir

128 sought to determine whether the presence of mild cognitive impairment independently increases the ri

129 is could reflect that activated microglia in mild cognitive impairment initially may adopt a protecti

130 between ST6GAL1 mutations and conversion of mild cognitive impairment into clinical Alzheimer's dise

131 healthy people and patients exhibiting late mild cognitive impairment leading to Alzheimer disease.

132 Community-dwelling older adults with mild cognitive impairment living in an urban area in Chi

133 As mild cognitive impairment may be a contributor to poorer

134 ing early-stage Alzheimer's disease (AD) and mild cognitive impairment (MCI of the Alzheimer's type).

135 301) and clinically diagnosed patients with mild cognitive impairment (MCI) (n = 178), AD dementia (

136 hy controls (HC), 33 patients with diagnosed mild cognitive impairment (MCI) and 30 patients with Alz

137 DNI), including cognitively unimpaired (CU), mild cognitive impairment (MCI) and AD dementia patients

138 d choroid plexus tissue samples and CSF from mild cognitive impairment (MCI) and AD patients to analy

139 diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI) and AD.

140 Monocyte/macrophages of patients with mild cognitive impairment (MCI) and Alzheimer disease (A

141 plays a crucial role in the pathogenesis of mild cognitive impairment (MCI) and Alzheimer's disease

142 Memory disruption in mild cognitive impairment (MCI) and Alzheimer's disease

143 g the cognitive performance in patients with mild cognitive impairment (MCI) and Alzheimer's disease

144 clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's particip

145 an men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been es

146 t study was conducted among individuals with mild cognitive impairment (MCI) and cognitively normal i

147 al tau level, cognitive decline, and risk of mild cognitive impairment (MCI) and dementia; (2) whethe

148 in patients with Parkinson disease (PD) and mild cognitive impairment (MCI) and in patients with PD

149 Depression is common in individuals with mild cognitive impairment (MCI) and may confer a higher

150 lar risk factors with the risk of developing mild cognitive impairment (MCI) and MCI progression to d

151 of patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) and subjects with subjec

152 is) of patients with Alzheimer's disease and mild cognitive impairment (MCI) are defective in amyloid

153 The introduction of mild cognitive impairment (MCI) as a diagnostic category

154 s with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) can serve to predict pro

155 spinal fluid (CSF) and blood KLK8 for AD and mild cognitive impairment (MCI) due to AD.

156 ) on brain atrophy and cognitive function in mild cognitive impairment (MCI) due to Alzheimer's disea

157 ngs make liberal use of the descriptive term mild cognitive impairment (MCI) for those with cognitive

158 his modelling study, we included people with mild cognitive impairment (MCI) from single-centre and m

159 2) discriminates patients with diabetes with mild cognitive impairment (MCI) from those with normal c

160 es and biomarker data from 562 subjects with mild cognitive impairment (MCI) from two national studie

161 oved predictive accuracy, especially for the Mild Cognitive Impairment (MCI) group.

162 The search for early biomarkers of mild cognitive impairment (MCI) has been central to the

163 Associations of sleep characteristics with mild cognitive impairment (MCI) have been examined in cr

164 nsion treatment on incidence of dementia and mild cognitive impairment (MCI) in 9361 participants in

165 AD polygenic risk score (PRS) could identify mild cognitive impairment (MCI) in adults who were only

166 olipoprotein E epsilon4 (APOE-e4) allele and mild cognitive impairment (MCI) in elderly subjects.

167 Because mild cognitive impairment (MCI) is a prodromal stage for

168 Mild cognitive impairment (MCI) is an intermediate stage

169 Mild cognitive impairment (MCI) is common in early Parki

170 tem of patients with Alzheimer's disease and mild cognitive impairment (MCI) is deregulated with high

171 e-onset Alzheimer disease (LOAD) preceded by mild cognitive impairment (MCI) is the most common type

172 d with greater risk of incident dementia and mild cognitive impairment (MCI) later in life.

173 es ranging from normal aging to AD-including mild cognitive impairment (MCI) not converting or conver

174 individuals with high risk of progression to mild cognitive impairment (MCI) or AD.

175 increase the opportunity to delay or prevent mild cognitive impairment (MCI) or Alzheimer disease (AD

176 ting activities and decreased odds of having mild cognitive impairment (MCI) or Alzheimer disease hav

177 eveloped risk estimates for the incidence of mild cognitive impairment (MCI) or dementia among cognit

178 west tertile were more likely to progress to mild cognitive impairment (MCI) or dementia in Cox propo

179 Background For individuals with mild cognitive impairment (MCI) or dementia, elevated br

180 oE4(+/-) patients with clinical diagnosis of mild cognitive impairment (MCI) or early AD when compare

181 ealthy control participants, and a cohort of mild cognitive impairment (MCI) patients with four-year

182 n differences between healthy controls (HC), mild cognitive impairment (MCI) patients, and AD patient

183 d DLB and AD, as well as in their prodromal, mild cognitive impairment (MCI) phases.

184 sease (AD) continuum, the prodromal state of mild cognitive impairment (MCI) precedes AD dementia and

185 Postmortem brains of mild cognitive impairment (MCI) rather than symptomatic

186 dent discovery [cognitively normal (CN), 19; mild cognitive impairment (MCI) risk, 43; MCI, 6] and re

187 miRNAs in serum samples from AD patients and Mild cognitive impairment (MCI) subjects relative to hea

188 : To optimize prediction of progression from mild cognitive impairment (MCI) to AD dementia by combin

189 (18)F-FDG PET for predicting conversion from mild cognitive impairment (MCI) to Alzheimer dementia (A

190 id deposition related to the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD

191 tment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia.

192 factors for predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease (

193 ed as a clinical marker for progression from mild cognitive impairment (MCI) to dementia.

194 Mild cognitive impairment (MCI) was classified into MCI

195 with SCeVD (n = 22), preclinical AD (pAD) + mild cognitive impairment (MCI) without SCeVD (pAD/MCI w

196 470 patients (138 with AD, 332 with mild cognitive impairment (MCI)) were selected from the

197 ulation method during sleep in patients with mild cognitive impairment (MCI), a precursor of AD, and

198 this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to de

199 ly unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD

200 nts with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD

201 ts (mean age 63-69 years), participants with mild cognitive impairment (MCI), Alzheimer's disease, an

202 nitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with A

203 udy included 83 cognitively normal (CN), 160 mild cognitive impairment (MCI), and 73 AD subjects who

204 dy, we tested the prediction accuracy of AD, mild cognitive impairment (MCI), and amyloid deposition

205 ry plexus (SCP) in Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively intact

206 RI with hippocampal subfield analysis of AD, mild cognitive impairment (MCI), and healthy subjects.

207 ascular dementia (VD), senile dementia (SD), mild cognitive impairment (MCI), and other neurodegenera

208 ch of four groups: Alzheimer's disease (AD), mild cognitive impairment (MCI), FCD and healthy control

209 subset of CN participants who progressed to mild cognitive impairment (MCI), heightened memory aware

210 tions to prevent or delay cognitive decline, mild cognitive impairment (MCI), or dementia are uncerta

211 tment to prevent or delay cognitive decline, mild cognitive impairment (MCI), or dementia is uncertai

212 from individuals with Alzheimer's dementia, Mild Cognitive Impairment (MCI), or no cognitive impairm

213 (MR) spectroscopic imaging in subjects with mild cognitive impairment (MCI), patients with Parkinson

214 n epsilon4 non-carriers diagnosed with AD or mild cognitive impairment (MCI), SNPs within the BACE2 l

215 pulation) of both dementia and its prodrome, mild cognitive impairment (MCI), which are characterized

216 Mild cognitive impairment (MCI), which often precedes AD

217 ts with Alzheimer's disease (AD) dementia or mild cognitive impairment (MCI).

218 herpesviruses on development of dementia or mild cognitive impairment (MCI).

219 outcomes for adults with normal cognition or mild cognitive impairment (MCI).

220 for clinicians, especially in patients with mild cognitive impairment (MCI).

221 gy, which is already evident at the stage of mild cognitive impairment (MCI).

222 estigate the nature of olfactory deficits in mild cognitive impairment (MCI).

223 l outcomes following a clinical diagnosis of mild cognitive impairment (MCI).

224 related neuronal structures in patients with mild cognitive impairment (MCI).

225 (AD) in a large population of patients with mild cognitive impairment (MCI).

226 cipants (42 with dementia due to AD; 65 with mild cognitive impairment (MCI); 95 control participants

227 e clinical BDNF data in patients with AD and mild cognitive impairment (MCI, a prodromal stage of AD)

228 er disease (AD; n = 300), memory-predominant mild cognitive impairment (MCI; n = 75), or neurological

229 %; 73.8 [8.5] years) and 55 individuals with mild cognitive impairment (MCI; women, 38%; 76.9 [7.3] y

230 = 70; subjective cognitive concerns: n = 74; mild cognitive impairment [MCI]: n = 29, AD dementia: n

231 Forty-five patients with mild cognitive impairment (mean age +/- SD, 72.69 +/- 6.

232 ognitively normal subjects, 95 subjects with mild cognitive impairment (Mini-Mental State Examination

233 s and 767 cognitively impaired participants (mild cognitive impairment n = 420, Alzheimer's disease d

234 ively unimpaired (n = 153), or patients with mild cognitive impairment (n = 139) or Alzheimer's disea

235 individuals with normal cognition (n = 180), mild cognitive impairment (n = 148), or AD dementia (n =

236 omprising AD patients (n = 8), patients with mild cognitive impairment (n = 17), and healthy controls

237 Lewy bodies (n = 1), Parkinson disease with mild cognitive impairment (n = 2), corticobasal syndrome

238 anatomical differences between subjects with mild cognitive impairment (n = 530) and Alzheimer's dise

239 n = 62) and prodromal (amyloid-beta-positive mild cognitive impairment, n = 49) Alzheimer's disease h

240 (22 years before the estimated median age at mild cognitive impairment onset of 44 years), although t

241 ) and 20 amyloid-beta-positive patients with mild cognitive impairment or Alzheimer's disease dementi

242 4 clinical variables from 1909 patients with Mild Cognitive Impairment or Alzheimer's Disease to trai

243 onship with age, beta-amyloid pathology, and mild cognitive impairment or clinical AD diagnostic stat

244 ere classified into those with conversion to mild cognitive impairment or dementia during the study (

245 al change in personality before the onset of mild cognitive impairment or dementia was identified.

246 a combined group of participants with either mild cognitive impairment or dementia with Alzheimer's c

247 diagnosis of cognitive impairment (combined mild cognitive impairment or dementia) at 2 years as out

248 ontrolled trials of CCT in older adults with mild cognitive impairment or dementia.

249 personality traits occur before the onset of mild cognitive impairment or dementia.

250 ative pathology, resulting in mixed forms of mild cognitive impairment or dementia.

251 own about the efficacy of CCT in people with mild cognitive impairment or dementia.

252 ontrolled trials of CCT in older adults with mild cognitive impairment or dementia.

253 on from normal cognition to symptom onset of mild cognitive impairment or dementia: Paired Associates

254 e conducted (11)C-UCB-J PET on patients with mild cognitive impairment or early Alzheimer disease (AD

255 l individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia.

256 ) in the diagnosis of patients with amnestic mild cognitive impairment or mild Alzheimer's disease (a

257 95% CI, 0.69-0.95) and the combined rate of mild cognitive impairment or probable dementia (20.2 vs

258 nitive impairment and a composite outcome of mild cognitive impairment or probable dementia.

259 The study included 262 patients with mild cognitive impairment or subjective cognitive declin

260 cohort (n = 125) with normal cognition (NC), mild cognitive impairment, or AD dementia.

261 e final diagnosis of Alzheimer disease (AD), mild cognitive impairment, or neither at fluorine 18 ((1

262 h a clinical diagnosis of Alzheimer disease, mild cognitive impairment, or normal cognition underwent

263 We prospectively recruited a pool of 117 mild cognitive impairment patients (45 amnestic type and

264 ed effects models) and amyloid-beta-negative mild cognitive impairment patients (beta = 0.67, P < 0.0

265 ) had accelerated p-tau217 compared to other mild cognitive impairment patients (beta = 0.79, P < 0.0

266 phage polarization and improved cognition in mild cognitive impairment patients on omega-3 supplement

267 dies indicated greater tau binding in AD and mild cognitive impairment patients than in controls in a

268 Mild cognitive impairment patients who later converted t

269 Nine subjects (5 with AD, 4 with mild cognitive impairment) received a 90-min dynamic (S)

270 een those with normal cognitive function and mild cognitive impairment regarding baseline health and

271 ariables of baseline health, the presence of mild cognitive impairment remained a significant predict

272 ry and cognitive decline in normal aging and mild cognitive impairment remains elusive.

273 Participants with mild cognitive impairment spanned the A-T- (42%), A+T- (

274 ing Initiative cohort, including progressive mild cognitive impairment, stable MCI and Normal Control

275 ects than in healthy controls (P < 0.001) or mild cognitive impairment subjects (P = 0.029).

276 l HE subjects, 4 AD subjects, and 2 amnestic mild cognitive impairment subjects after a bolus injecti

277 Methods: A set of 11 Alzheimer and 12 mild cognitive impairment subjects and a set of 20 multi

278 VT was greater in mild cognitive impairment subjects than controls in the

279 ween groups of Alzheimer's disease patients, mild cognitive impairment subjects, and normal controls.

280 clinically diagnosed Alzheimer's disease or mild cognitive impairment subjects.

281 les of an independent group of Alzheimer and mild cognitive impairment subjects.

282 mmation is increased relative to controls in mild cognitive impairment than it is for dementia, and t

283 ) and increases the risk of progression from mild cognitive impairment to AD.

284 ), followed by those modelling prediction of mild cognitive impairment to Alzheimer's disease (n=15),

285 s we subsequently study the progression from mild cognitive impairment to dementia, demonstrating tha

286 es the full range of cognitive deficits from mild cognitive impairment to dementia.

287 ort cognitive test: the Test Your Memory for Mild Cognitive Impairment (TYM-MCI) in the diagnosis of

288 eimer's disease kindred, who did not develop mild cognitive impairment until her seventies, three dec

289 During 24569 person-years, mild cognitive impairment was diagnosed in 104 (5.1%) in

290 mer disease (AD), and subjects with amnestic mild cognitive impairment were characterized in a study

291 estionnaire, incident Alzheimer dementia and mild cognitive impairment were documented in detailed an

292 .+/-6.7, 55-87 years) with dementia prodrome mild cognitive impairment were recruited in the SMART (S

293 n postmortem brain tissue from subjects with mild cognitive impairment, when Abeta trimers are abunda

294 on in microglial activation in subjects with mild cognitive impairment, while subjects with Alzheimer

295 a-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheim

296 to Alzheimer's disease and those with stable mild cognitive impairment who had a follow-up time of at

297 that Abeta34 is elevated in individuals with mild cognitive impairment who later progressed to dement

298 controls, but also between individuals with Mild Cognitive Impairment who were later diagnosed with

299 s) with clinical diagnosis of probable AD or mild cognitive impairment with positive PET biomarker fo

300 hout a loss of muscle mass) in patients with mild cognitive impairment, with progression of cognitive